Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Koh, Youngil  [Clear All Filters]
2024
Kim J, Byun JMin, Hong J, Koh Y, Shin D-Y, Kim TMin, Yoon S-S, Park H, Kim I. Treatment outcomes and prognostic factors of patients with lymphoblastic lymphoma in East Asia. Medicine (Baltimore). 2024;103(7):e37100.
2023
Lee E, Lee S, Park S, Son Y-G, Yoo J, Koh Y, Shin D-Y, Lim Y, Won J. Asymmetric anti-CLL-1×CD3 bispecific antibody, ABL602 2+1, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine release. J Immunother Cancer. 2023;11(10).
Park W, Byun JMin, Hong J, Kim I, Shin D-Y, Park S, Koh Y, Yoon S-S. Comparison of the effect of DLI according to cell sources in relapsed AML after allogeneic stem cell transplantation. Ann Hematol. 2023.
Cho H, Yoon DHyun, Shin D-Y, Koh Y, Yoon S-S, Kim SJin, Do YRok, Lee G-W, Kwak J-Y, Park Y, et al. Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404). Cancer Res Treat. 2023.
Liu J, Min S, Kim D, Park J, Park E, Pei S, Koh Y, Shin D-Y, Byun JMin, Ko M, et al. Pharmacological GLUT3 salvage augments the efficacy of vitamin C-induced TET2 restoration in acute myeloid leukemia. Leukemia. 2023.
Hong J, Park H-K, Chang S-H, Byun JMin, Shin D-Y, Koh Y, Yoon S-S, Choi Y, Kim I. A randomized phase II study of acyclovir for the prevention of chemotherapy-induced oral mucositis in patients undergoing autologous hematopoietic stem cell transplantation. BMC Oral Health. 2023;23(1):1008.
2022
Facon T, Moreau P, Martin TG, Spicka I, Oriol A, Koh Y, Lim A, Mikala G, Rosiñol L, Yağci M, et al. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis. Hematol Oncol. 2022.
Yi JHo, Jeong SHyun, Kim SJin, Yoon DHyun, Kang HJin, Koh Y, Kim JSeok, Lee W-S, Yang D-H, Do YRok, et al. Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts. Cancer Res Treat. 2022.
Kim DHyun, Seo J, Shin D-Y, Koh Y, Hong J, Kim I, Yoon S-S, Byun JMin. Reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for patients with myelofibrosis. Blood Res. 2022.
2021
Jung EHee, Shin D-Y, Hong J, Kim I, Yoon S-S, Koh Y, Byun JMin. Identification of an Optimal Population for Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Mature T and NK Cell Neoplasms. In Vivo. 2021;35(4):2379-2390.
2018
Jeong SHyun, Song H-N, Park JSeong, Yang D-H, Koh Y, Yoon S-S, Lee HWon, Eom HSeok, Won J-H, Kim WSeog, et al. Allogeneic stem cell transplantation for patients with natural killer/T-cell lymphoid malignancy: a multicenter analysis comparing upfront and salvage transplantation. Biol Blood Marrow Transplant. 2018.
2016
Byun JMin, Kim H-L, Shin D-Y, Koh Y, Yoon S-S, Seong M-W, Park SSup, Kim JHee, Lee Y-G, Kim I. The Impact of Methylenetetrahydrofolate Reductase C677T Polymorphism on Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation with Methotrexate Prophylaxis. PLoS One. 2016;11(10):e0163998.